1,003 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
What Lies Ahead for Healthcare ETFs in Q4 Earnings? http://www.zacks.com/stock/news/731805/what-lies-ahead-for-healthcare-etfs-in-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-731805 Jan 24, 2020 - With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings? http://www.zacks.com/stock/news/731666/will-pfizers-pfe-biopharma-unit-boost-its-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-731666 Jan 24, 2020 - Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU http://www.zacks.com/stock/news/731626/pharma-stock-roundup-jjs-mixed-q4-roche-novartis-new-drugs-approval-in-eu?cid=CS-ZC-FT-analyst_blog|stock_roundup-731626 Jan 24, 2020 - J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates http://www.zacks.com/stock/news/729100/5-big-drug-biotech-stocks-set-to-trump-q4-earnings-estimates?cid=CS-ZC-FT-earnings_esp-729100 Jan 22, 2020 - Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza http://www.zacks.com/stock/news/729180/horizon-therapeutics-gets-fda-approval-for-eye-drug-tepezza?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-729180 Jan 22, 2020 - Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Merck's Keytruda Could Face Direct Competition from New Chinese Drug https://www.fool.com/investing/2020/01/21/mercks-keytruda-could-face-direct-competition-from.aspx?source=iedfolrf0000001 Jan 21, 2020 - Chinese drugmaker BeiGene would compete directly with Merck's cancer superdrug.
AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer https://www.fool.com/investing/2020/01/21/astrazeneca-and-merck-get-an-fda-priority-review-f.aspx?source=iedfolrf0000001 Jan 21, 2020 - The blockbuster drug is already approved for three other types of tumors.
Is Merck & Co. (MRK) a Profitable Pick for Value Investors? http://www.zacks.com/stock/news/726509/is-merck-co-mrk-a-profitable-pick-for-value-investors?cid=CS-ZC-FT-analyst_blog|value_stocks-726509 Jan 20, 2020 - Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.
Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat? http://www.zacks.com/stock/news/722277/will-jj-jnj-roll-out-pharma-q4-earnings-with-a-beat?cid=CS-ZC-FT-analyst_blog|earnings_preview-722277 Jan 17, 2020 - J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.
Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates http://www.zacks.com/stock/news/722255/pharma-stock-roundup-lly-dermira-buyout-offer-pipeline-regulatory-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-722255 Jan 17, 2020 - Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

Pages: 123456...101

Page 1>